The NUT midline carcinoma (NMC) is a rare but fatal cancer for which systematic testing of therapy options has never been performed.
The generation of a substantial number of relevant PC xenografts and cell lines with stage-specific characteristics has significantly improved the potential application of preclinical models for testing of therapy efficacy.
The discovery of toxin-induced and genetic models in both rodents and nonhuman primates has allowed for the comprehensive testing of therapies before they reach the clinic.
Such mice could prove critical for the testing of therapies to prevent beta cell destruction.
Further development and testing of therapies based upon improved understanding of the complex pathophysiology of this common and disabling complication is urgently required.
Such a model would be invaluable for the development and testing of therapies to improve remyelination and to restore cognitive function.
Thus endogenous and exogenous OPCs form myelin sheaths in our slice model, allowing testing of therapies enhancing both strategies for improving remyelination.
An animal model that can accurately inform on the effects of demyelination and remyelination on complex functions would be invaluable for the development and testing of therapies to improve remyelination and to restore neurological function.
Neoadjuvant therapy with letrozole could be considered a sensitivity test of endocrine therapy that might be incorporated into strategies to individualize adjuvant treatment according to response [ 95].
This is the true test of sequential therapy as if the standard total dose of carboplatin is given, adding other drugs later leads to greatly prolonged therapy, which could be almost considered maintenance therapy.
